The Latest Analyst Ratings For Kymera Therapeutics
Portfolio Pulse from Benzinga Insights
Kymera Therapeutics (NASDAQ:KYMR) has received mixed analyst ratings over the past three months, with a recent increase in the average 12-month price target to $52.83. Analysts have adjusted their ratings and price targets, reflecting changing market dynamics and company performance. Kymera's financials show a strong revenue growth rate of 55.33% but challenges in asset utilization and profitability.
November 01, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kymera Therapeutics has received a mix of bullish and somewhat bullish ratings from analysts, with a new average price target of $52.83, up from $42.50. The company's revenue growth is strong, but it faces challenges in asset utilization and profitability.
The increase in the average price target and the majority of bullish ratings suggest a positive short-term outlook for Kymera Therapeutics. The company's strong revenue growth supports this, although challenges in asset utilization and profitability may temper expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100